Table 2.
HI and MN antibody responses against the homologous A/Astana/6/05RG strain
| Dose level (n) | Response to vaccine based on: |
|||||
|---|---|---|---|---|---|---|
| Seroconversiona |
Geometric mean increaseb |
Seroprotectionc |
||||
| HI | MN | HI | MN | HI | MN | |
| 7.5 μg (40) | 22 (55.0; 38.5–70.7) | 22 (55.0; 38.5–70.7) | 3.5 (2.4–5.2) | 4.37 (2.88–6.6) | 21 (52.5; 36.1–68.5) | 16 (40.0; 24.9–56.7) |
| 15 μg (40) | 28 (70.0; 53.5–83.4) | 27 (67.5; 50.9–81.4) | 4.7 (3.3–6.7) | 7.46 (4.79–11.6) | 23 (57.5; 40.9–73) | 22 (55.0; 38.5–70.7) |
a
Seroconversion was defined as a ≥4-fold rise in antibody titer compared to the day zero titer. Data are the number of responders, with the percentage and 95% CI provided in parentheses.
b
The geometric mean increase (with 95% CI in parentheses) reflects the increase in the GMT.
c
Seroprotection is the number of volunteers whose titer was ≥1:40 (with the percentage of responders and the 95% CI shown in parentheses).